11 – 20 of 28
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2006
-
Mark
Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
(
- Contribution to journal › Article
-
Mark
Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids
(
- Contribution to journal › Article
- 2005
-
Mark
Potent synergic effect between ibuprofen and azoles on Candida resulting from blockade of efflux pumps as determined by FUN-1 staining and flow cytometry
(
- Contribution to journal › Article
- 2004
-
Mark
Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model.
(
- Contribution to journal › Article
-
Mark
Dicloxacillin and erythromycin at high concentrations increase ICAM-1 expression by endothelial cells: a possible factor in the pathogenesis of infusion phlebitis.
(
- Contribution to journal › Article
-
Mark
Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimens
(
- Contribution to journal › Article
-
Mark
A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea.
(
- Contribution to journal › Article
-
Mark
Pseudomonas aeruginosa-induced infection and degradation of human wound fluid and skin proteins ex vivo are eradicated by a synthetic cationic polymer
(
- Contribution to journal › Article
- 2002
-
Mark
The treatment of Haemophilus influenzae acute otitis media with amoxicillin protects against reinfection but not against structural changes
(
- Contribution to journal › Article
-
Mark
Comparison of the antibacterial activities of ampicillin, ciprofloxacin, clarithromycin, telithromycin and quinupristin/dalfopristin against intracellular non-typeable Haemophilus influenzae.
(
- Contribution to journal › Article